Shares of this Ashish Kcholia stock jumped around 3 percent in Thursday’s trading session after the company secured a spot in Forbes ‘200 Best Under a Billion’ List. In the past month, the company’s stock has delivered returns of more than 20 percent to its stakeholders.
With a market capitalization of Rs 1,130.10 crores, the stocks of Beta Drugs Limited opened their trading session on Thursday at Rs 1,180 and currently trades at Rs 1,176. The stock witnessed an intra-day high of Rs 1,200 indicating a gain of around 3 percent as compared to the previous close of Rs 1,167.90.
In a recent regulatory filing, the company announced the pharma company, being one of the two pharma companies featured, to secure a spot in the esteemed Forbes list of the ‘200 Best Under a Billion’ companies.
“Being recognized by Forbes is a tremendous honor and a validation of the hard work and dedication of the entire team. Our commitment to innovation, quality, and delivering value to our stakeholders has been integral to our success.”, commented Mr. Rahul Batra, Chairman and Managing Director of Beta Drugs Limited.
Mr. Ashish Kacholia, one of the well-known ace investors based in India, has invested in the stocks of Beta Drugs Limited. He took an entry into the stock in March 2019, and, as per the latest quarter ended September 2023, he cumulatively holds 12.03 lakh equity shares equating to a 12.52 percent stake in the company.
Having a walkthrough of the annual financial reports published by the company, the prime business indicators such as the operating revenues and net profits consistently reported an increase in numbers.
The former recently moved up from Rs 183 crores during FY21-22 to Rs 227 crores during FY22-23, and, the latter, during the same time horizon, took a shift from Rs 24 crores to Rs 30 crores.
The latest shareholding pattern of the company portrays the Promoters holding a 66.73 percent stake, Public (retail) investors holding a 32.93 percent stake, and the remaining small stake of 0.32 percent is held by Foreign Institutional Investors (FIIs).
Beta Drugs Limited is an India-based pharma company engaged in the business of manufacturing as well as selling ‘Oncology’ products. The company offers its products in the form of capsules, tablets, injections, oral formulations, etc.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
